Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: Efficacy and safety of non-VKA oral anticoagulants in selected populations

Thrombosis Research

Volumn 134, Issue 2, 2014, Pages 227-233

  Prandoni, Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Deep vein thrombosis; Fragile; Low molecular weight heparin; Non VKA oral anticoagulant; Pulmonary embolism; Vitamin K antagonist

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CANADA; CLINICAL STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; LONG TERM CARE; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME; ACUTE DISEASE; BLEEDING; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; HEMORRHAGE; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 84905121366     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.013     Document Type: Review

References (75)

1. F.A. Anderson Jr., H.B. Wheeler, R.J. Goldberg, D.W. Hosmer, N.A. Patwardhan, and B. Jovanovic et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study Arch Intern Med 151 1991 933 938
2. A.T. Cohen, G. Agnelli, F.A. Anderson, J.I. Arcelus, D. Bergqvist, and J.G. Brecht et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality Thromb Haemost 98 2007 756 764
3. P.T. Vaitkus, A. Leizorovicz, A.T. Cohen, A.G.G. Turpie, C.G. Olsson, and S.Z. Goldhaber et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients Thromb Haemost 93 2005 76 79
4. S.Z. Goldhaber, and H. Bounameaux Pulmonary embolism and deep vein thrombosis Lancet 379 2012 1835 1846
5. National Institute for Health and Clinical Excellence Venous thromboembolism costing report: Implementing NICE guidance Available at: http://www.nice.org.uk/nicemedia/pdf/CG046VenousThromboembolismCostingReport. pdf 2007
6. K. Kroger, J. Kupper-Nybelen, C. Moerchel, T. Moysidis, C. Kienitz, and I. Schubert Prevalence and economic burden of pulmonary embolism in Germany Vasc Med 17 2012 303 309
7. P. Prandoni, F. Noventa, A. Ghirarduzzi, V. Pengo, E. Bernardi, and R. Pesavento et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients Haematologica 92 2007 199 205
8. A. Spyropoulos, and J. Lin Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations J Manag Care Pharm 13 2007 475 486
9. W. Ageno, G. Agnelli, D. Imberti, M. Moia, G. Palareti, and R. Pistelli et al. Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry Thromb Res 121 2008 751 756
10. I.M. van Korlaar, C.Y. Vossen, F.R. Rosendaal, E.G. Bovill, M. Cushman, and S. Naud et al. The impact of venous thrombosis on quality of life Thromb Res 114 2004 11 18
11. V. Pengo, A.W.A. Lensing, M.H. Prins, A. Marchiori, B.L. Davidson, and F. Tiozzo et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N Engl J Med 350 2004 2257 2264
12. A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galiè, and P. Pruszczyk et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 29 2008 2276 2315
13. B.I. Eriksson, D.J. Quinlan, and J.W. Eikelboom Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism Annu Rev Med 62 2011 41 57
14. P.P. Kneeland, and M.C. Fang Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism Patient Prefer Adherence 4 2010 51 60
15. D.W. Barritt, and S.C. Jordan Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial Lancet 1 1960 1309 1312
16. C.I. Lagerstedt, C.G. Olsson, B.O. Fagher, B.W. Oqvist, and U. Albrechtsson Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis Lancet 2 1985 515 518
17. D.P. Brandjes, H. Heijboer, H.R. Büller, M. de Rijk, H. Jagt, and J.W. ten Cate Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis N Engl J Med 327 1992 1485 1489
18. J.A. Heit, D.N. Mohr, M.D. Silverstein, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study Arch Intern Med 160 2000 761 768
19. J.N. Fiessinger, M.V. Huisman, B.L. Davidson, H. Bounameaux, C.W. Francis, and H. Eriksson et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JAMA 293 2005 681 689
20. van Gogh Investigators, H.R. Büller, A.T. Cohen, B. Davidson, H. Decousus, and A.S. Gallus et al. Idraparinux versus standard therapy for venous thromboembolic disease N Engl J Med 357 2007 1094 1104
21. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
22. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, and P. Mismetti et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 2014 764 772
23. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
24. The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
25. M.H. Prins, and A.W.A. Lensing Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism Thromb J 11 2013 13
26. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
27. The Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
28. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
29. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, and D. Baanstra et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
30. T.A. Brighton, J.W. Eikelboom, K. Mann, R. Mister, A. Gallus, and P. Ockelford et al. Low-dose aspirin for preventing recurrent venous thromboembolism N Engl J Med 367 2012 1979 1987
31. C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, and M. Silingardi et al. Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 366 2012 1959 1967
32. R.L. Silverstein, K.A. Bauer, M. Cushman, C.T. Esmon, W.B. Ershler, and R.P. Tracy Venous thrombosis in the elderly: more questions than answers Blood 110 2007 3097 3101
33. M.M. Samama Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment Drugs Aging 28 2011 177 193
34. L. López-Jiménez, M. Montero, J.A. González-Fajardo, J.I. Arcelus, C. Suárez, and J.L. Lobo et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE) Haematologica 91 2006 1046 1051
35. F.A. Spencer, J.M. Gore, D. Lessard, C. Emery, L. Pacifico, and G. Reed et al. Venous thromboembolism in the elderly. A community-based perspective Thromb Haemost 100 2008 780 788
36. J.A. Caprini, V.F. Tapson, T.M. Hyers, A.L. Waldo, A.K. Wittkowsky, and R. Friedman et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs J Vasc Surg 42 2005 726 733
37. B.K. Poulsen, E.L. Grove, and S.E. Husted New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function Drugs 72 2012 1739 1753
38. A. Leizorovicz, V. Siguret, and D. Mottier Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS) Thromb Res 128 2011 27 34
39. Bayer Pharma AG Xarelto® Summary of Product Characteristics Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000944/WC500057108.pdf 2013
40. Boehringer Ingelheim International GmbH Pradaxa® Summary of Product Characteristics Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000829/WC500041059.pdf 2013
41. Bristol-Myers Squibb, Pfizer EEIG Eliquis® Summary of Product Characteristics Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002148/WC500107728.pdf 2013
42. A.Y. Lee Management of thrombosis in cancer: primary prevention and secondary prophylaxis Br J Haematol 128 2005 291 302
43. N. Levitan, A. Dowlati, S.C. Remick, H.I. Tahsildar, L.D. Sivinski, and R. Beyth et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291
44. G.H. Lyman Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis Cancer 117 2011 1334 1349
45. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e419S e494S
46. M.H. Prins, A.W.A. Lensing, R. Bauersachs, B. van Bellen, H. Bounameaux, and T.A. Brighton et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies Thromb J 11 2013 21
47. R.H. White The epidemiology of venous thromboembolism Circulation 107 2003 14 18
48. D. Weberova, P. Weber, H. Kubesova, H. Meluzinova, V. Polcarova, and P. Ambrosova et al. Occurrence of pulmonary embolism among 260 in-patients of acute geriatric department aged 65 + years in 2005-2010 Adv Gerontol 25 2012 506 512
49. A. Cherubini, S. Del Signore, J. Ouslander, T. Semla, and J.P. Michel Fighting against age discrimination in clinical trials J Am Geriatr Soc 58 2010 1791 1796
50. D. Poli, E. Antonucci, S. Testa, A. Tosetto, W. Ageno, and G. Palareti Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation Circulation 124 2011 824 829
51. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295
52. C.E. Frost, S. Nepal, Y. Barrett, and F. LaCreta Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban J Thromb Haemost 7 455 2009 PP-MO-407
53. M.M. Samama, S. Kunitada, A. Oursin, F. Depasse, and S. Heptinstall Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults Thromb Res 126 2010 e286 e293
54. D. Kubitza, M. Becka, A. Roth, and W. Mueck Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Curr Med Res Opin 24 2008 2757 2765
55. A.G.G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas Management consensus guidance for the use of rivaroxaban - an oral, direct Factor Xa inhibitor Thromb Haemost 108 2012 876 886
56. K. Defeo, C. Hayes, M. Chernick, J. van Ryn, and S.K. Gilmour Use of dabigatran etexilate to reduce breast cancer progression Cancer Biol Ther 10 2010 1001 1008
57. M.N. Levine, C. Gu, H.A. Liebman, C.P. Escalante, S. Solymoss, and D. Deitchman et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer J Thromb Haemost 10 2012 807 814
58. S.R. Kahn, W. Lim, A.S. Dunn, M. Cushman, F. Dentali, and E.A. Akl et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e195S e226S
59. M.K. Gould, D.A. Garcia, S.M. Wren, P.J. Karanicolas, J.I. Arcelus, and J.A. Heit et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e227S e277S
60. J. van Es, R.A. Douma, P.W. Kamphuisen, V.E. Gerdes, P. Verhamme, and P.S. Wells et al. Clot resolution after 3 weeks of anticoagulant treatment of pulmonary embolism: comparison of computed tomography and perfusion scintigraphy J Thromb Haemost 11 2013 679 685
61. R. Varin, S. Mirshahi, P. Mirshahi, C. Klein, J. Jamshedov, and J. Chidiac et al. Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban Thromb Res 131 2013 e100 e109
62. C. Hammerstingl, B. Pötzsch, and G. Nickenig Resolution of giant left atrial appendage thrombus with rivaroxaban Thromb Haemost 109 2013 583 584
63. P. Bernhardt, H. Schmidt, C. Hammerstingl, M. Hackenbroch, T. Sommer, and B. Luderitz et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging Am J Cardiol 94 2004 801 804
64. S. Konstantinides, and S.Z. Goldhaber Pulmonary embolism: risk assessment and management Eur Heart J 33 2012 3014 3022
65. S. Laporte, P. Mismetti, H. Décousus, F. Uresandi, R. Otero, and J.L. Lobo et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry Circulation 117 2008 1711 1716
66. P.D. Stein, and J.W. Henry Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy Chest 108 1995 978 981
67. W. Kasper, S. Konstantinides, A. Geibel, M. Olschewski, F. Heinrich, and K.D. Grosser et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry J Am Coll Cardiol 30 1997 1165 1171
68. P.D. Stein, and F. Matta Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused Am J Med 125 2012 465 470
69. N. Kucher, E. Rossi, M. De Rosa, and S.Z. Goldhaber Massive pulmonary embolism Circulation 113 2006 577 582
70. G. Meyer, E. Vicaut, T. Danays, G. Agnelli, C. Becattini, and J. Beyer-Westendorf et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism N Engl J Med 370 2014 1402 1411
71. M. Sharifi, C. Bay, F. Schwartz, and L. Skrocki Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge Clin Cardiol 37 2014 78 82
72. C.D. Barbosa, M.M. Balp, K. Kulich, N. Germain, and D. Rofail A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence Patient Prefer Adherence 6 2012 39 48
73. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 2005 487 497
74. L. Bamber, M.Y. Wang, M.H. Prins, C. Ciniglio, R. Bauersachs, and A.W. Lensing et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis Thromb Haemost 110 2013 732 741
75. M. Prins, L. Bamber, S. Cano, M. Wang, A. Lensing, and R. Bauersachs Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism Blood (ASH Annu Meet Abstr) 120 2012 1163